Anti-aging research investor Jim O’Neill, President Donald Trump’s pick to lead the National Science Foundation, has failed to gain support for his appointment from the Senate.Members of the Senate Committee on Health, Education, Labor and Pensions on Wednesday thwarted O’Neill’s nomination to lead the nearly $9 billion research organization, despite having confirmed him to be the deputy secretary of Health and Human Services in 2025.Committee chairman Sen. Bill Cassidy (R-LA) said just before a scheduled vote on approving O’Neill’s nomination that the vote was canceled. O’Neill, who was a close business associate of venture capitalist and Trump mega-donor Peter Thiel before joining the Trump administration, was removed from the deputy HHS position in February as part of a pre-midterm election change in leadership in the department.In addition to being a chief adviser to Health Secretary Robert F. Kennedy Jr., O’Neill was tapped to be acting director of the Centers for Disease Control and Prevention after Trump and Kennedy fired the Senate-confirmed director, Susan Monarez, last year following a disagreement over the childhood vaccine schedule.Cassidy said on Wednesday that several members of the committee were skeptical of O’Neill’s ability to lead NSF objectively, given his tenure at HHS.“As acting CDC Director, Mr. O’Neill did not do enough to stand up for science and against irresponsible decisions and statements from Secretary Kennedy,” Cassidy said. “His role in the firing of Dr. Susan Monarez raised further concerns about the independent judgment he would bring to NSF.”Cassidy added that, despite liking O’Neill personally, “this time requires leadership and fortitude, and standing up for what is right.”A White House spokesperson confirmed for the Washington Examiner that Trump did not pull O’Neill’s nomination before the committee’s scheduled vote.NSF funds fundamental research projects across primarily nonmedical fields of science and engineering, but O’Neill has been steeped in health policy work since the beginning of his career, particularly in pushing the boundaries of anti-aging science.O’Neill started his career in the early 2000s as a speechwriter for the first HHS secretary under President George W. Bush. By 2007, he was named principal associate deputy secretary of HHS, overseeing a range of policy areas, including pandemic preparedness.In October 2008, O’Neill moved to the private sector to manage Thiel’s Mithril Capital Management, funding anti-aging research projects. O’Neill later served as CEO of SENS Research Foundation, which focuses on medical research to prevent and reverse the aging process.While working with Thiel, O’Neill advised investments in more than 60 science and technology companies before joining the board of directors at Advantage Therapeutics in 2023.Advantage Therapeutics specializes in Alzheimer’s disease and other neurodegenerative conditions. The company’s signature product, the compound AD04, is undergoing early clinical trials in Europe as an immunotherapeutic for early-stage Alzheimer’s.The failure of O’Neill’s nomination comes following the White House’s decision to pull the nomination of Dr. Heidi Overton for the Food and Drug Administration commissioner position, which was also scheduled for a vote in the Senate health committee on Wednesday.HOW MEASLES REGAINED A FOOTHOLD IN THE UNITED STATESCassidy said the decision to pull her nomination was a surprise, given productive talks with members of the committee to secure her confirmation.“Unfortunately, with the limited time left, confirming a permanent FDA commissioner appears to fall to Senate Democrats,” Cassidy said.
Trump nomination of anti-aging advocate for National Science Foundation fails in Senate
Full Article
Original Source
Read the full article at Washingtonexaminer →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.